Real World Analysis of the Efficacy, Prognosis and Safety of Daratumumab, Carfilzomib, and Dexamethasone (DKD) in Relapsed or Refractory Multiple Myeloma Patients

被引：0
|
作者：
Fu, Chengcheng [1 ]
You, Hongying [1 ]
Jin, Song [1 ]
Wang, Panfeng [2 ]
Yan, Lingzhi [1 ]
Zhang, Liying [3 ]
Lu, Tingting [4 ]
Gao, Xiao [5 ]
Jiang, Lei [6 ]
Qiu, Hongchun [7 ]
Shang, Jingjing [1 ]
Zhai, Yingying [1 ]
Yao, Weiqin [1 ]
Yan, Shuang [1 ]
Yan, Zhi [1 ]
Wu, Depei [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China
[2] Soochow Hopes Hematonosis Hosp, Suzhou, Peoples R China
[3] Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China
[4] Soochow Univ, Zhangjiagang Hosp, Suzhou, Peoples R China
[5] Zhangjiagang Hosp Tradit Chinese Med, Suzhou, Peoples R China
[6] Soochow Univ, Suzhou Hosp 9, Suzhou, Peoples R China
[7] Third Peoples Hosp Kunshan, Dept Hematol, Kunshan, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210102
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6992 / 6993
页数：2
相关论文
共 50 条
  • [1] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [2] Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naive Relapsed Multiple Myeloma: Multicenter Real-World Experience
    Mansour, Razan
    Davis, James A.
    Minchak, Megan
    Atallah, Rawan
    Saif, Md Saiful Islam
    Logan, Emerson
    Tabak, Carine
    Rashid, Aliya
    Dima, Danai
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [3] A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
    Rocchi, Serena
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    di Giovanni Bezzi, Chiara
    Scalese, Marco
    Dozza, Luca
    Marzocchi, Giulia
    Martello, Marina
    Barila, Gregorio
    Antonioli, Elisabetta
    Staderini, Michela
    Buda, Gabriele
    Petrini, Mario
    Cea, Michele
    Quaresima, Micol
    Furlan, Anna
    Bonalumi, Angela
    Cavo, Michele
    Zamagni, Elena
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 41 - 50
  • [4] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary E.
    Feng, Huaibao
    Brun, Nikolai Constantin
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [5] SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
    Plesner, T.
    Arkenau, H. T.
    Lokhorst, H. M.
    Gimsing, P.
    Krejcik, J.
    Lemech, C.
    Minnema, M. C.
    Lassen, U.
    Ahmadi, T.
    Yeh, H.
    Guckert, M.
    Brun, N. C.
    Lisby, S.
    Basse, L.
    Palumbo, A.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 104 - 104
  • [6] Retrospective Analysis of a Group of Early Relapsed Multiple Myeloma (MM) Patients Treated by Daratumumab Carfilzomib Dexamethasone (DKD)
    Ghonema, Rasha
    Hasaneen, Mahmoud
    Alshemmari, Salem
    Khadadah, Fatima
    El'sheashaey, Ahmed
    Elkady, Dina
    Hamadah, Abdulaziz
    Pandita, Ramesh
    Alhuraiji, Ahmad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S542 - S543
  • [7] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis
    Stork, Martin
    Spicka, Ivan
    Radocha, Jakub
    Minarik, Jiri
    Jelinek, Tomas
    Jungova, Alexandra
    Pavlicek, Petr
    Pospisilova, Lenka
    Sedlak, Frantisek
    Straub, Jan
    Pika, Tomas
    Knechtova, Zdenka
    Fidrichova, Anna
    Boichuk, Ivanna
    Sevcikova, Sabina
    Maisnar, Vladimir
    Hajek, Roman
    Pour, Ludek
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1501 - 1511
  • [8] Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
    Martin Stork
    Ivan Spicka
    Jakub Radocha
    Jiri Minarik
    Tomas Jelinek
    Alexandra Jungova
    Petr Pavlicek
    Lenka Pospisilova
    Frantisek Sedlak
    Jan Straub
    Tomas Pika
    Zdenka Knechtova
    Anna Fidrichova
    Ivanna Boichuk
    Sabina Sevcikova
    Vladimir Maisnar
    Roman Hajek
    Ludek Pour
    Annals of Hematology, 2023, 102 : 1501 - 1511
  • [9] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Xu, Jiadai
    Liu, Peng
    BLOOD, 2024, 144 : 7052 - 7053
  • [10] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
    Dimopoulos, Meletios A.
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David S.
    Weisel, Katja
    Gavriatopoulou, Maria
    Oriol, Albert
    Rabin, Neil K.
    Nooka, Ajay
    Qi, Ming
    Ding, Bifeng
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    BLOOD, 2020, 136
12345